1064 Biol. Pharm. Bull. 42, 1064–1068 (2019) Vol. 42, No. 7 Review

Effects of Distigmine on the Mechanical Activity of Urinary Bladder Smooth Muscle Keisuke Obara* and Yoshio Tanaka Department of Chemical Pharmacology, Faculty of Pharmaceutical Sciences, Toho University; 2–2–1 Miyama, Funabashi, Chiba 274–8510, Japan. Received February 28, 2019; accepted April 24, 2019

Distigmine bromide (distigmine) is a reversible cholinesterase (ChE) inhibitor. Its principle clinical application is in the treatment of myasthenia gravis. Distigmine is also used as a remedy for dysuria and glaucoma. Its effectiveness in the management of dysuria has been demonstrated in several clinical re- ports. Distigmine may improve (enhance) urinary bladder smooth muscle (UBSM) contraction during mic- turition by inhibiting (ACh) decomposition. However, the pharmacological effects of distigmine on UBSM have not been adequately studied so far. In this review article, we summarize the reported effects of distigmine on the contractile responses elicited by exogenous and endogenous ACh in isolated UBSM preparations. We also discuss the effects of distigmine on the UBSM basal tone and the contractile response of UBSM to ATP, which is co-released with ACh from parasympathetic nerve terminals. Key words distigmine bromide; urinary bladder smooth muscle; cholinesterase inhibitor; acetylcholine; adenosine triphosphate

1. INTRODUCTION 2. EFFECTS OF DISTIGMINE ON UBSM CONTRAC- TILE RESPONSES ELICITED BY EXOGENOUS CON- Distigmine bromide (distigmine) is a carbamate cholinester- STRICTORS ase(ChE)inhibitorfirstsynthesizedbySchmidinthe1950s1) (Fig. 1). It and other carbamate ChE inhibitors have been used During urination, ACh and ATP are released from the to treat myasthenia gravis in Asia, the Middle East, and Eu- parasympathetic nerve ending in the UB in response to rope.2–5) Distigmine has also been used to treat glaucoma in nerve excitation.30–36) Distigmine inhibits Japan.6–8) Distigmine has also been applied as a remedy for (AChE) activity in the UB.37,38) Therefore, it is presumed that dysuria in Japan since its release there in 1968. It was report- distigmine enhances the contractile force of the UBSM by ed that distigmine has a therapeutic effect on neurogenically increasing ACh concentration in the synaptic cleft between underactive bladder caused by surgery, spinal cord injury, the parasympathetic nerve ending and the UBSM. To test and chronic diseases such as diabetes.9–21) It is also effective this assumption, we investigated the effects of distigmine on against drug-induced dysuria22,23) and benign prostatic hyper- ACh-induced contractions in guinea pig UBSM. As shown in plasia (BPH)-induced dysuria.24–26) Distigmine was reported Fig. 2A, distigmine (3 × 10−8−3 × 10−6 M) enhanced the ACh- to be clinically effective against both underactive bladder and induced contractile response in the UBSM in a concentration- dysuria. In recent years, distigmine efficacy was validated dependent manner.39–41) with various animal disease models.27–29) A study using the balloon method reported that distigmine The therapeutic effect of distigmine in the management potentiated the increase in guinea pig intravesical pressure of urinary disorders is explained by its ChE inhibition. This induced by intravenous ACh administration.39) The duration of mechanism enhances the contractile force of the urinary the enhancement of ACh-induced guinea pig UB contraction bladder smooth muscle (UBSM) by increasing the concentra- by distigmine was commensurate with its inhibitory effect on tion of acetylcholine (ACh) in the synaptic cleft between the ChE in the UB.42) These results, then, support the presumption parasympathetic nerve terminal and the UBSM. However, the that distigmine enhances the contractile force of UBSM by pharmacological effects of distigmine on the UBSM have sel- increasing ACh. dom been investigated despite the fact that numerous clinical ATP is also a parasympathetic UBSM constrictor. Thus, we reportshavedemonstrateditsefficacyindysuriatreatment.In also examined the effect of distigmine on ATP-induced guinea this review article, we present a synopsis of studies in which the effects of distigmine on the contractile responses elicited by exogenous and endogenous ACh were examined in isolated UBSM preparations. We also discuss the effects of distig- mine on the UBSM basal tone and the contractile response of UBSM to the neurotransmitter ATP, which is co-released with ACh from the parasympathetic nerve terminals.

Fig. 1. Structure of Distigmine Bromide (Distigmine)

* To whom correspondence should be addressed. e-mail: [email protected] © 2019 The Pharmaceutical Society of Japan Vol. 42, No. 7 (2019) Biol. Pharm. Bull. 1065

Fig. 2. Effects of Distigmine on Concentration-Response Curves for Acetylcholine (ACh) (A) and ATP (B)-Induced Contraction of Guinea Pig Uri- nary Bladder Smooth Muscle ACh and ATP were cumulatively added to the bath solution either in the absence or presence of distigmine. Ordinate: % contraction induced by 3 × 10−4 M acetylcholine in the absence of drugs (A) or by a single administration of 10−4 M ATP before the experiment (B). Abscissa: negative logarithms of acetylcholine (A) or ATP (B) concen- trations (M). Data are means ± S.E.M. for n = 4–24 experiments. ** p < 0.01 vs. control. Data were reproduced with permission of the authors of Ōyō Yakuri/Pharmacomet- rics, 85, 101–114 (2013)41) (Fig. 2A) and Biol. Pharm. Bull., 40, 1092–1100 (2017)42) (Fig. 2B). pig UBSM contractile response. However, distigmine (10−6 M) mediated by the release of endogenous ACh from the para- had no effect on the ATP concentration-response curves in sympathetic nerve terminals without affecting ATP-mediated guinea pig UBSM42) (Fig. 2B). contraction. Similar results were obtained for mouse bladder.45)

3. EFFECTS OF DISTIGMINE ON UBSM CONTRAC- 4. EFFECTS OF DISTIGMINE ON THE BASAL TONE TILE RESPONSES ELICITED BY ENDOGENOUS OF UBSM PARASYMPATHETIC NEUROTRANSMITTERS Very close observation disclosed that distigmine marginally In human UBSM, distigmine may enhance contractile increased the basal tone of guinea pig UBSM39–41,46) (Fig. 4). responses to parasympathetic nerve excitement induced by Distigmine also very slightly increased basal tone in human electrical field stimulation (EFS).43) However, it is unknown UBSM.4) In contrast, the carbamate ChE inhibitors neostig- which endogenous parasympathetic neurotransmitters cause mine and strongly enhanced the basal tone this potentiation. Guinea pig UBSM contractile responses to of guinea pig UBSM39,40,46) (Fig. 4). This discrepancy may be EFS consisted of a contractile component sensitive to the mus- resolved by the fact that whereas and pyridostig- carinic receptor antagonist atropine and another affected by mine are exclusively , distigmine may also have a the purinergic receptor-desensitizing agent α,β-methylene ATP paradoxical effect. In rat bladder, distigmine (α,β-mATP). The application concentrations of these agents inhibited the binding of [3H] N-methyl scopolamine to the −6 −4 were 10 and 10 M, respectively (Fig. 3A). Therefore, these muscarinic receptors. Its Ki value was 1.33 ± 0.11 µM whereas contractions were caused by both ACh (the atropine-sensitive that for neostigmine was >50µM. Therefore, the latter should component) and ATP (the α,β-mATP-sensitive component).44) have no effect on the muscarinic receptors.47) Our mechanistic To confirm that distigmine augments the ACh-induced study demonstrated that distigmine (3 × 10−5 M) suppressed contractile component, we examined its effects on contraction bethanechol-induced contractile responses in guinea pig generated in the presence of α,β-mATP (10−4 M). Distigmine UBSM and urethral smooth muscle.39) Bethanechol is a syn- (10−6 M) substantially enhanced the contractile component thetic ester which is not decomposed by ChE. and subsequent atropine (10−6 M) administration almost com- ChE inhibitors may increase UBSM basal tone by stimulat- pletely suppressed it (Fig. 3B). Therefore, distigmine clearly ing the release of ACh from parasympathetic nerve endings. augmented the ACh-mediated contractile component.44) This mechanism was inferred from the effects of ChE inhibi- We also examined the effects of distigmine on the EFS- tors on nicotine receptors. Distigmine and neostigmine inhibit induced contractile component generated in the presence of the binding of [3H] epibatidine to nicotine receptors in rat ce- atropine to verify that distigmine does not influence ATP- rebral cortex. The Ki values were 22.9 ± 3.3 µM for distigmine induced contraction. Distigmine (10−6M) did not significantly and 18.8 ± 3.3 µM for neostigmine.47) We investigated whether affect the contractile component generated in the presence neostigmine mediated the increase in UBSM basal tone via of atropine (10−6 M) (p >0.05 for atropine (10−6 M) . atro- ACh derived from parasympathetic nerves. This effect was pine (10−6 M) + distigmine (10−6 M)). In fact, the contractile not significantly affected by tetrodotoxin (TTX; 10−6 M) component generated in the presence of atropine was me- (p >0.05 for neostigmine (3× 10−5 M) vs. neostigmine diated by ATP because it was significantly suppressed by (3 × 10−5 M) + TTX (10−6 M)) (our unpublished observation). α,β-mATP (10−4 M) (p <0.05foratropine(10−6 M) vs. atropine Therefore, ACh derived from the parasympathetic nerves (10−6 M) + distigmine (10−6 M) + α,β-mATP (10−4 M); p < 0.01 did not significantly contribute to the neostigmine-induced for atropine (10−6 M) + distigmine (10−6 M) vs. atropine increase in UBSM basal tone. Non-neurogenic ACh was con- (10−6 M) + distigmine (10−6 M) + α,β-mATP (10−4 M))44) (Fig. tinuously detected in UB tissue irrespective of the presence of 3C). These results suggest that distigmine enhances UB con- urothelium.48) However, the contribution of the urothelium was traction during urination by potentiating UBSM contraction greater than that of the UBSM.48) Therefore, neurogenic ACh 1066 Biol. Pharm. Bull. Vol. 42, No. 7 (2019)

Fig. 3. Electrical Field Stimulation (EFS)-Induced Contractile Responses of Guinea Pig Urinary Bladder (UB) Preparation A: Representative trace showing EFS-induced contractions and the effects of atropine (10−6 M), α,β-methylene ATP (α,β-mATP) (10−4 M), and tetrodotoxin (TTX) (3 × 10−7 M). All drugs were applied cumulatively in the indicated order. B: Representative traces showing the potentiating effects of distigmine (10−6 M) and the inhibi- tory effects of atropine (10−6 M) on EFS-evoked contractions in the presence of α,β-mATP (10−4 M). C: Representative traces showing the effects of distigmine (10−6 M) and α,β-mATP (10−4 M) on EFS-evoked contractions in the presence of atropine (10−6 M). All experiments were conducted in the presence of phentolamine (10−6 M), pro- pranolol (10−6 M), and indomethacin (3 × 10−6M)toblockthepotentialeffectsofendogenousnoradrenalineandprostaglandins.Dataweremodifiedwiththepermissionof the authors of Eur. J. Pharmacol., 809, 209–214 (2017).44)

Fig. 4. Direct Contractile Effects of Distigmine (A) and Neostigmine (B) on Isolated Guinea Pig Urinary Bladder Preparations Thecontractileeffectsofdistigmineandneostigminewereevaluatedasthetransientmaximumresponsesappearingusuallywithin5minafteradministration(Max.) and the tension levels at 30 and 60 min after administration. Distigmine and neostigmine were applied to the bath solution as a single administration. Ordinate: % contrac- tions induced by 3 × 10−4 ACh. Abscissa: negative logarithms of the distigmine concentrations (M). Data are collected from n =2–5experimentsperdistigmineconcen- tration and n = 2–7 experiments per neostigmine concentration and reproduced with the permission of the authors of Ōyō Yakuri/Pharmacometrics, 75,85–96(2008).40) may not be involved in this process. Rather, non-neurogenic nerve excitation. The inhibition of ChE by neostigmine and components may participate in it. It is possible, then, that ACh distigmine may increase UBSM basal tone by activating the is continuously supplied to UB tissue without parasympathetic muscarinic receptors. However, non-neurogenic ACh might be Vol. 42, No. 7 (2019) Biol. Pharm. Bull. 1067

stimulation mediated by ACh and ATP. Distigmine augments the contractile response of UBSM by enhancing the neuro- genic ACh-mediated contractile component resulting from the inhibition of ACh degradation (Fig. 5). Suppression of non- neurogenic ACh degradation by ChE inhibitors may increase UBSM basal tone. However, a possible anticholinergic action of distigmine counteracts this effect (Fig. 5). Thus, this drug has only a slight net effect on the apparent UBSM basal tone. Therapeutic agents for underactive bladder are limited. There- fore, elucidation of the pharmacological effects and molecular mechanisms of distigmine could facilitate the development of new drugs for the management of lower urinary tract dysfunc- tion.

Conflict of Interest The authors declare no conflict of interest. Fig. 5. SchematicSummaryofthePresentReview REFERENCES suppressed by the anticholinergic action of distigmine so that the basal tone only slightly increases.  1) SchmidO.USPatent2789981(1957). 2) Pateisky K. Treatment of myasthenia gravis pseudoparalytica; clini- 5. EFFECTS OF DISTIGMINE ON INTRACELLULAR cal testing and therapy with BC substances (BC40, BC47, BC48 and UBSM MECHANISMS BC51).Wien. Z. Nervenheilkd. Grenzgeb., 17,53–84(1959).  3) Emeryk E, Wasowicz B. Evaluation of “Ubretid” (BC 51) in the treatment of myasthenia gravis. Neurol. Neurochir. Psychiatr. Pol., It was reported that the muscarinic M2 receptors are ex- 13, 611–617 (1963). pressed to a greater extent than the M3 receptors in mammali- 4) Ishigaki K, Murakami T, Ito Y, Yanagisawa A, Kodaira K, Shi- 49) an UBSM. However, it is mainly the M3 receptor rather than shikura K, Suzuki H, Hirayama Y, Osawa M. Treatment approach the M2 receptor which triggers ACh-induced UBSM contrac- to congenital myasthenic syndrome in a patient with acetylcholine 49) tion in normal UB. Stimulation of the muscarinic M3 recep- receptordeficiency.No To Hattatsu, 41, 37–42 (2009). tor in UBSM activates phospholipase C (PLC) expected by the  5) Antimyasthenics.Martindale: the complete drug reference, 39th ed. typical intracellular mechanisms associated with Gq protein- (BrayfieldAed.)PharmaceuticalPress,London,pp.694–700(2017). 49) 6) Ishikawa S, Tsukahara S, Sato Y. Local administration of 1% coupled receptors. However, ACh-induced, M3 receptor- mediated UBSM contraction may be unaffected by PLC inhi- Ubretid in the handling of glaucoma, myasthenia gravis and esotro- pia. Ophthalmologica, 159, 339–362 (1969). bition. It could, however, be associated with the activation of 2+ 49)  7) Mizukawa T, Azuma I. Effects of Ubretid eye-drops upon glau- Rho kinase and/or voltage-dependent Ca channels. It was coma. Nihon Ganka Kiyo, 21,586–595(1970). recently proposed that the TRPC4 channel significantly con- 8) Sawada A, Hara K, Futa R, Ogata H. Pressure-lowering effect of a 2+ tributes to the mechanism underlying voltage-dependent Ca new cholinesterase inhibitor, Ubretid, on glaucoma. Nihon Ganka 50) channel activation. Therefore, distigmine-induced enhance- Kiyo, 22, 676–682 (1971). ment of ACh-mediated UBSM contraction may be triggered 9) Cameron MD. Distigmine bromide (Ubretid) in the prevention of by Rho kinase and/or TRPC4 channel activation. postoperative retention of urine. J. Obstet. Gynaecol. Br. Com- On the other hand, ATP-induced UBSM contraction is me- monw., 73, 847–848 (1966). diated mainly by ionotropic P2X1 receptors.51) P2X1 receptors 10) Oka N, Hasegawa S. Treatment of dysuria with anticholinesterases: are ligand-gated cation channels. When they are stimulated by Ubretid. Hinyokika Kiyo, 13,42–51(1967). ATP, they enhance Ca2+influxandsensitizationofthecon- 11) Yeo J, Southwell P, Hindmarsh E. Preliminary report on the effect of distigmine bromide on the neurogenic bladder. Med. J. Aust., 1, tractile apparatus to Ca2+.51) However, it is unlikely that dis- 116–120 (1973). tigmine affects ionotropic P2X1 receptor-coupled intracellular 12) Smith PH, Cook JB, Prasad EW. The effect of Ubretid on bladder pathways since it has no apparent influence on ATP-induced function after recent complete spinal cord injury. Br. J. Urol., 46, contraction in the UBSM. 187–192 (1974). Indirect or direct muscarinic receptor stimulators such as 13) Yeo J, Southwell P, Rutowski S, Marchant-Williams H. A further distigmine and bethanechol have been administered for many report on the effect of distigmine bromide (Ubretid) on the neuro- years to treat underactive bladder and remain the agents of genic bladder. Med. J. Aust., 2, 201–203 (1974). choice for the management of this symptom. In recent years, 14) Philp NH, Thomas DG. The effect of distigmine bromide on void- inginmaleparaplegicpatientswithreflexmicturition.Br. J. Urol., however,ONO-8055,anagonistoftheprostanoidEP2 and EP3 receptors, was reported to be effective in a radical hysterec- 52, 492–496 (1980). 15) TanakaY,MasumoriN,ItohN,FuruyaS,NishizawaO,Tsukamoto tomy-induced underactive monkey bladder model.27) Thus, T. Symptomatic and urodynamic improvement by oral distigmine prostanoid receptor-related drugs may prove to be efficacious bromide in poor voiders after transurethral resection of the prostate. therapeutic agents for the management of underactive bladder. Urology, 57, 270–274 (2001). 16) Bougas DA, Mitsogiannis IC, Mitropoulos DN, Kollaitis GC, Se- 6. CONCLUSION rafetinides EN, Giannopoulos AM. Clinical efficacy of distigmine bromide in the treatment of patients with underactive detrusor. Int. The UBSM contracts in response to parasympathetic nerve Urol. Nephrol., 36,507–512(2004). 1068 Biol. Pharm. Bull. Vol. 42, No. 7 (2019)

17) Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchi- 34) Brading AF, Mostwin JL. Electrical and mechanical responses of yama T, Yoshida K. Combination of a cholinergic drug and an guinea-pig bladder muscle to nerve stimulation. Br. J. Pharmacol., α-blocker is more effective than monotherapy for the treatment of 98, 1083–1090 (1989). voidingdifficultyinpatientswithunderactivedetrusor.Int. J. Urol., 35) Kura H, Obara K, Yabu H. Contractile responses to electrical field 11, 88–96 (2004). stimulation and ATP in guinea-pig urinary bladder. Comp. Bio- 18) Tanaka Y, Masumori N, Tsukamoto T, Furuya S, Furuya R, Ogura chem. Physiol. C., 102, 193–197 (1992).

H.Treatmentstrategyaccordingtofindingsonpressure-flowstudy 36) Shinkai M, Takayanagi I, Kato T. Tachykinin receptors of the NK2 for women with decreased urinary flow rate. Adv. Urol., 2009, type involved in the acetylcholine release by nicotine in guinea-pig 782985(2009). bladder. Br. J. Pharmacol., 108,759–762(1993). 19) Skolarikos A, Tyritzis S, Stamatiou K. Cholinergic drugs for treat- 37) Ito Y, Harada T, Fushimi K, Kagawa Y, Oka H, Nakazawa H, ment of recurrent urinary retention in high surgical risk/elderly BPH Homma R, Kato Y, Yamada S. Pharmacokinetic and pharmaco- patients. A pilot study. Minerva Urol. Nefrol., 64, 209–216 (2012). dynamic analysis of acetylcholinesterase inhibition by distigmine 20) Izumi K, Maolake A, Maeda Y, Shigehara K, Namiki M. Effects bromide in rats. Drug Metab. Pharmacokinet., 25,254–261(2010). of bethanechol chloride and distigmine bromide on postvoiding 38) Obara K, Chino D, Tanaka Y. Distigmine bromide produces sus- residual volume in patients with underactive bladder. Minerva Urol. tained potentiation of guinea-Pig urinary bladder motility by inhib- Nefrol., 66, 241–247 (2014). iting cholinesterase activity. Biol. Pharm. Bull., 40, 807–814 (2017). 21) Sugaya K, Kadekawa K, Onaga T, Ashitomi K, Mukouyama H, Na- 39) Horinouchi T, Aoki T, Akiyama R, Ono T, Shibano M, Tanaka kasone K, Shimabukuro H, Shimabukuro S, Matayoshi Y, Hokama Y, Koike K. Effects of distigmine, a long-acting cholinesterase S,TouyamaY,NishijimaS.Effectofdistigmineat5mgdailyinpa- inhibitor, on urinary bladder detrusor and urethra smooth muscles tients with detrusor underactivity. Nippon Hinyokika Gakkai Zasshi, of guinea-pig: pharmacological analysis in vitro and in vivo. Ōyō 105, 10–16 (2014). Yakuri/Pharmacometrics, 64,45–52(2003). 22) Eto R, Naganuma H, Fuji I. Antidepressant induced urinary re- 40) Sekiya S, Takahashi H, Seki Y, Teraoka A, Aikawa N, Tanaka Y, tention. Kyūshū Seishin Shinkei Igaku. Kyushu Neuropsych., 34, Koike K. Comparison of the effects of distigmine and neostigmine 308–311 (1988). on guinea-pig urinary bladder contractile functions assessed by in 23) Tsuno N, Miyata H, Nakayama K. Dysuria induced by psychotropic vivo and in vitro studies. Ōyō Yakuri/Pharmacometrics, 75, 85–96 drugs—appropriate usage of distigmine bromide (Ubretid), thera- (2008). peutic medicine of dysuria. No to Seishin no Igaku. Brain Sci. Ment. 41) Obara K, Aikawa N, Sato K, Chino D, Tanaka Y. Comparison Disord., 14,149–153(2003). of the effects of distigmine and bethanechol on guinea-pig lower 24) Katsumi T, Murayama K. Clinical effects of distigmine bromide urinary tracts contractile functions assessed by in vivo and in vitro (Ubretid), a cholinesterase inhibitor, on micturition disturbance studies. Ōyō Yakuri/Pharmacometrics, 85, 101–114 (2013). by benign prostatic hypertrophy—comparative study of distigmine 42) Obara K, Ogawa T, Chino D, Tanaka Y. The long-lasting enhancing bromide and the combination of distigmine bromide and adrenergic effect of distigmine on acetylcholine-induced contraction of guinea blocker. Hinyokika Kiyo, 38, 1089–1092 (1992). pig detrusor smooth muscle correlates with its anticholinesterase 25) Shibayama K, Makino T, Machida M, Hatori M. Combination activity. Biol. Pharm. Bull., 40, 1092–1100 (2017). therapy using Ubretid and prostal for micturition disturbance due to 43) Kullmann FA, Kurihara R, Ye L, Wells GI, McKenna DG, Burgard

benign prostatic hypertrophy. Jpn. Pharmacol. Ther., 20, 3839–3843 EC, Thor KB. Effects of the 5-HT4 receptor agonist, cisapride, on (1992). neuronally evoked responses in human bladder, urethra, and ileum. 26) Mikami Y, Araki I, Maezawa H, Takeda M. Efficacy of the com- Auton. Neurosci., 176, 70–77 (2013). bination therapy with alpha1-adrenergic blocker and distigmine 44) Obara K, Kobayashi Y, Chino D, Tanaka Y. Effect of distigmine on bromideinmicturitiondifficultysuggestingbenignprostatichyper- the contractile response of guinea pig urinary bladder to electrical plasia. Jpn. J. Urol. Surg., 20, 1207–1213 (2007). fieldstimulation.Eur. J. Pharmacol., 809, 209–214 (2017). 27) Matsuya H, Sekido N, Kida J, Mashimo H, Wakamatsu D, Okada 45) Obara K, Kobayashi Y, Chino D, Tanaka Y. Effects of distigmine H.EffectsofanEP2andEP3receptordualagonist,ONO-8055,on onelectricalfieldstimulation-inducedcontractionofmouseurinary a radical hysterectomy-induced underactive bladder model in mon- bladder smooth muscles. Pharmacology, 99, 106–113 (2017). keys. Low. Urin. Tract Symptoms, 10, 204–211 (2018). 46) Nagabukuro H, Doi T. Differential effects of TAK-802, a selective 28) Tatemichi S, Tsuchioka K, Yonekubo S, Maruyama K, Kobayashi acetylcholinesterase inhibitor, and carbamate acetylcholinesterase

M. Effects of silodosin, an α1A-adrenoceptor antagonist, and distig- inhibitors on contraction of the detrusor smooth muscle of the mine, an acetylcholinesterase inhibitor, and their combined effects guinea pig. Life Sci., 77,3276–3286(2005). on impaired voiding function in Zucker diabetic fatty rats. Pharma- 47) Harada T, Fushimi K, Kato A, Ito Y, Nishijima S, Sugaya K, Yama- cology, 95,285–292(2015). da S. Demonstration of muscarinic and nicotinic receptor binding 29) Obara K, Chino D, Tanaka Y. The recovery effects of distigmine on activities of distigmine to treat detrusor underactivity. Biol. Pharm. guinea pig detrusor underactivity induced by anticholinergic drugs. Bull., 33,653–658(2010). Ōyō Yakuri/Pharmacometrics, 91,25–39(2016). 48) Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama 30) Ambache N, Zar MA. Non-cholinergic transmission by post-gan- Y, Murakami S. Non-neuronal cholinergic system in human bladder glionic motor neurones in the mammalian bladder. J. Physiol., 210, urothelium. Urology, 67,425–430(2006). 761–783 (1970). 49) FrazierEP,PetersSL,BravermanAS,RuggieriMRSr,MichelMC. 31) Burnstock G, Dumsday B, Smythe A. Atropine resistant excitation Signal transduction underlying the control of urinary bladder smooth of the urinary bladder: the possibility of transmission via nerves muscle tone by muscarinic receptors and beta-adrenoceptors. Nau- releasing a purine nucleotide. Br. J. Pharmacol., 44,451–461(1972). nyn Schmiedebergs Arch. Pharmacol., 377, 449–462 (2008). 32) Westfall DP, Fedan JS, Colby J, Hogaboom GK, O’Donnell JP. 50) Griffin CS, Bradley E, Dudem S, Hollywood MA, McHale NG, Evidence for a contribution by purines to the neurogenic response Thornbury KD, Sergeant GP. Muscarinic receptor induced contrac- of the guinea-pig urinary bladder. Eur. J. Pharmacol., 87,415–422 tions of the detrusor are mediated by activation of TRPC4 channels. (1983). J. Urol., 196, 1796–1808 (2016). 33) Moss HE, Burnstock G. A comparative study of electrical field 51) Kennedy C. ATP as a cotransmitter in the autonomic nervous sys- stimulation of the guinea-pig, ferret and marmoset urinary bladder. tem. Auton. Neurosci., 191,2–15(2015). Eur. J. Pharmacol., 114,311–316(1985).